Does Tirzepatide Work Better Than Semaglutide?

On average, yes — in the only large head-to-head trial of the two branded weight-management products (SURMOUNT-5, which compared Zepbound® directly against Wegovy®, each titrated to its maximum tolerated dose), participants on tirzepatide lost an average of 20.2% of their body weight over 72 weeks versus 13.7% on semaglutide.[1] That’s a real, well-documented difference. But “works better on average” is not the same as “works better for you”: tolerability, health history, and cost all shape which medication is the right prescription, and plenty of people do their best on semaglutide. The choice between them is a medical decision your provider makes with you — here’s the evidence they’re weighing.

Why tirzepatide averages higher: one pathway vs. two

Semaglutide activates the GLP-1 receptor — mimicking a gut hormone that signals fullness to your brain, slows stomach emptying, quiets food cravings, and steadies blood sugar.[2]

Tirzepatide activates the GLP-1 receptor and the GIP receptor.[3] That second pathway appears to add appetite and metabolic effects on top of what GLP-1 activation alone achieves — the leading explanation for the larger average results.

Branded products, for the record: semaglutide is sold as Wegovy® (FDA-approved for chronic weight management)[4] and Ozempic® (FDA-approved to improve glycemic control in type 2 diabetes)[5], both from Novo Nordisk. Tirzepatide is sold as Zepbound® (FDA-approved for chronic weight management)[6] and Mounjaro® (FDA-approved to improve glycemic control in type 2 diabetes)[7], both from Eli Lilly.

The numbers, properly attributed

All figures below come from clinical trials of the brand-name, FDA-approved products — and individual results vary. The first two are separate trials, each against its own placebo, run years apart in different groups of people; they can’t be lined up against each other to rank the medications. Only SURMOUNT-5 tested the two head to head:

• STEP-1 (Wegovy®): average weight reduction of 14.9% over 68 weeks at the 2.4 mg once-weekly dose, versus 2.4% with placebo, alongside diet and activity changes.[8]
• SURMOUNT-1 (Zepbound®/tirzepatide): up to roughly 21% average reduction over 72 weeks at the highest dose.[9]
• SURMOUNT-5 (head-to-head, Zepbound® vs. Wegovy®): 20.2% vs. 13.7% average reduction over 72 weeks, with each medication titrated to its maximum tolerated dose[1] — the cleanest direct comparison available, and it favored tirzepatide.

Note what these numbers are: averages, from long trials, of branded products, in combination with lifestyle change. They are not a guarantee of any individual outcome, and compounded preparations — which are not FDA-approved — were not the products studied.

Where the comparison gets more even

Side effects. Both medications share the same core profile — nausea, diarrhea, constipation, vomiting, mostly early and mostly easing with time.[2][3] Neither is reliably “gentler”; individual tolerance differs more than the molecules do. Some people who struggle on one do fine on the other, in either direction.

Response is individual. Every trial average contains strong responders and modest responders on both medications. A person’s response to semaglutide doesn’t predictably map onto what tirzepatide would have done for them, and vice versa.

Cost. Tirzepatide is the more expensive molecule. Through Ladies First, plans with compounded semaglutide start at $219 per 28 days of medication on a 12-week plan ($249 flexible); compounded tirzepatide runs $309 per 28 days on a 12-week plan ($339 flexible); oral semaglutide is $279. Compounded preparations are a separate regulatory category — prepared by state-licensed compounding pharmacies, not FDA-approved, and not generic equivalents or substitutes for the branded products — a distinction we keep explicit. Brand-name options are also available through your provider. Over a year-plus of treatment, that price gap is a legitimate factor, and your provider treats it as one.

History and track record. Semaglutide has the longer track record: its first brand, Ozempic®, was FDA-approved in December 2017,[10] while tirzepatide (Mounjaro®) was FDA-approved in May 2022,[3] which some people and providers weigh in semaglutide’s favor.

How a provider actually chooses

During intake, a licensed provider looks at your full picture: how much weight matters medically for you, conditions like insulin resistance or PCOS, medication history (including any prior GLP-1 experience), tolerability risk, and what’s sustainable for your budget — because the medication you can stay on beats the medication with the better average. Sometimes the answer is start with semaglutide and reassess; sometimes it’s tirzepatide first; sometimes it’s a switch later (Can You Switch from Semaglutide to Tirzepatide?).

The bottom line

Tirzepatide outperformed semaglutide on average in the head-to-head trial of the branded products — that part isn’t controversial. But averages don’t take medications; you do. The right prescription is the one matched to your health history, your tolerance, and your real life, and that’s a determination a licensed medical provider makes during intake — not a ranking you pick from.

Get the recommendation that fits you. Answer a few health questions online — about 3–5 minutes, free — and a medical provider licensed in your state reviews your history and recommends the appropriate medication, usually within 48 hours. Your treatment ships only after a licensed medical provider approves your plan.

See If You Qualify →

Sources

1. SURMOUNT-5 — “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” N Engl J Med 2025;393(1):26-36. pubmed.ncbi.nlm.nih.gov/40353578
2. Semaglutide — StatPearls, NCBI Bookshelf. ncbi.nlm.nih.gov/books/NBK603723. “The mechanisms through which semaglutide delivers its benefits in lowering blood glucose levels and promoting weight loss involve the activation of GLP-1 receptors primarily located in the gastrointestinal tract, pancreas, and brain.”
3. Tirzepatide — StatPearls, NCBI Bookshelf. ncbi.nlm.nih.gov/books/NBK585056. “Tirzepatide is a novel medication approved by the US Food and Drug Administration (FDA) for treating type 2 diabetes mellitus (T2DM).”
4. Wegovy® (semaglutide) Prescribing Information — DailyMed. dailymed.nlm.nih.gov. “to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.”
5. Ozempic® (semaglutide) Prescribing Information — DailyMed. dailymed.nlm.nih.gov. “as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.”
6. Zepbound® (tirzepatide) Prescribing Information — DailyMed. dailymed.nlm.nih.gov. “to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.”
7. Mounjaro® (tirzepatide) Prescribing Information — DailyMed. dailymed.nlm.nih.gov. “as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.”
8. STEP-1 — semaglutide 2.4 mg once weekly in adults with overweight or obesity. N Engl J Med 2021. pubmed.ncbi.nlm.nih.gov/33567185. “The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo”
9. SURMOUNT-1 — tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022. pubmed.ncbi.nlm.nih.gov/35658024. “In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight.”
10. Drugs@FDA: Ozempic® (NDA 209637), original FDA approval December 5, 2017. accessdata.fda.gov

Free 3–5 minute check · Provider review within 24–48 hours · 100% self-pay · Cancel any time